Oncolytics Biotech Inc. Files 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Jul 8, 2025 · CIK: 1129928

Sentiment: neutral

Topics: reporting, foreign-private-issuer, administrative

Related Tickers: ONCY

TL;DR

ONCOLYTICS BIOTECH INC (ONCY) filed a 6-K, confirming Canadian base and 20-F annual report filing.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on July 8, 2025, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations sector. This filing indicates they will file annual reports under Form 20-F.

Why It Matters

This filing provides routine disclosure for foreign private issuers, informing investors about the company's reporting status and location.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of July 2025.

Where is Oncolytics Biotech Inc. headquartered?

Oncolytics Biotech Inc. is headquartered in Calgary, Alberta, Canada, with its principal executive offices located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

Which form does Oncolytics Biotech Inc. use for its annual reports?

Oncolytics Biotech Inc. indicates it files annual reports under cover of Form 20-F.

What is the SIC code for Oncolytics Biotech Inc.?

The Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the filing date of this 6-K report?

This Form 6-K report was filed as of and for the period ending July 8, 2025.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 8, 2025 regarding ONCOLYTICS BIOTECH INC (ONCY).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing